In Colorado, miRagen Therapeutics, a biopharmaceutical company which develops microRNA-targeting therapies for treating diseases and cancer, has acquired Signal Genetics. The acquisition was funded partly by a $40 million investment by Fidelity Management and Research Company, Brace Pharma Capital, Atlas Venture, Boulder Ventures, JAFCO Co., Ltd., MP Healthcare Venture Management, MRL Ventures (Merck), Remeditex Ventures, and others. Signal Genetics, a publicly traded company based in California, has been working on genetic testing technology for multiple myeloma. Signal’s name and stock symbol will be changed to that of miRagen Therapeutics, as miRagen acquired 96% of Signal’s stock. Signal’s executives and directors will all resign as part of the acquisition.
Latest article
Biobased tennis balls offer a sustainable spin
In the UK, Central Saint Martins graduate Noé Chouraqui has created Point, a 3D-printed tennis ball made from biobased and recyclable materials.
Conventional tennis...
Fleece to function: Design student creates wool-based electronics
In London, Central Saint Martins graduate Hinna Khan has created a simple electronic device from conductive wool. Dubbed WoolTech, Khan was able to replace...
Flax to the Future: Natural fiber boosts padel racket performance
In France, a flax-fiber composite is finding a home in rackets for padel, a fast-growing sport that marries tennis and squash.
Dubbed TeXtreme R...